Worldwide Metabolic Disorders Drugs Industry to 2030 - Players Include Novo Nordisk, Astra Zeneca and Johnson & Johnson Among Others - ResearchAndMarkets.com

The "Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market as it emerges from the COVID-19 shut down.

The global metabolic disorders drugs market is expected to grow from $143.16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%.

Companies Mentioned

• Sanofi S.A
• Novo Nordisk A/S
• AstraZeneca Plc
• Johnson & Johnson
• Merck & Co

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020. Asia Pacific was the second largest region accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market.

Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Metabolic Disorders Drugs Market Characteristics

4. Metabolic Disorders Drugs Market Product Analysis

5. Metabolic Disorders Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Metabolic Disorders Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Metabolic Disorders Drugs Market Trends and Strategies

8. Impact of COVID-19 on Metabolic Disorders Drugs

9. Metabolic Disorders Drugs Market Size and Growth

9.1. Market Size

9.2. Historic Market Growth, Value ($ Billion)

9.2.1. Drivers of the Market

9.2.2. Restraints on the Market

9.3. Forecast Market Growth, Value ($ Billion)

9.3.1. Drivers of the Market

9.3.2. Restraints on the Market

10. Metabolic Disorders Drugs Market Regional Analysis

10.1. Global Metabolic Disorders Drugs Market, 2020, by Region, Value ($ Billion)

10.2. Global Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region

10.3. Global Metabolic Disorders Drugs Market, Growth and Market Share Comparison, by Region

11. Metabolic Disorders Drugs Market Segmentation

11.1. Global Metabolic Disorders Drugs Market, Segmentation by Type

11.2. Global Metabolic Disorders Drugs Market, Segmentation by Distribution Channel

11.3. Global Metabolic Disorders Drugs Market, Segmentation by Route of Administration

11.4. Global Metabolic Disorders Drugs Market, Segmentation by Drug Classification

11.5. Global Metabolic Disorders Drugs Market, Segmentation by Mode of Purchase

12. Metabolic Disorders Drugs Market Metrics

12.1. Metabolic Disorders Drugs Market Size, Percentage of GDP, 2015-2025, Global

12.2. Per Capita Average Metabolic Disorders Drugs Market Expenditure, 2015-2025, Global

For more information about this report visit https://www.researchandmarkets.com/r/6axoap

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005773/en/